Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and developing …

Neuroendocrine prostate cancer (NEPC) has increasingly become a clinical challenge. The
mechanisms by which neuroendocrine (NE) cells arises from prostate adenocarcinoma cells …

Despite recent therapeutic advances, prostate cancer remains a leading cause of cancer-
related death. A subset of castration-resistant prostate cancers become androgen receptor …

Abtract Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the
normal development of several endoderm-derived organs, including the prostate gland …

Epigenetic processes govern prostate cancer (PCa) biology, as evidenced by the
dependency of PCa cells on the androgen receptor (AR), a prostate master transcription …

Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …

Prostate cancer is the second most commonly diagnosed malignancy among men
worldwide. Recurrently mutated in primary and metastatic prostate tumors, FOXA1 encodes …

Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American
men. While androgen deprivation has remained as the cornerstone of prostate cancer …

Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical
challenge with new generation second-line hormonal therapies affording limited …